Mirum Pharmaceuticals (MIRM) to Release Quarterly Earnings on Wednesday

Mirum Pharmaceuticals (NASDAQ:MIRM) is anticipated to post its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect Mirum Pharmaceuticals to post earnings of ($0.29) per share and revenue of $96.64 million for the quarter.

Mirum Pharmaceuticals Price Performance

Mirum Pharmaceuticals stock opened at $52.70 on Wednesday. The stock’s 50 day moving average is $45.44 and its 200 day moving average is $42.74. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The firm has a market cap of $2.53 billion, a P/E ratio of -26.09 and a beta of 0.96. Mirum Pharmaceuticals has a one year low of $23.14 and a one year high of $53.49.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Robert W. Baird lifted their price objective on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Finally, Citigroup lifted their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Mirum Pharmaceuticals currently has an average rating of “Buy” and an average target price of $57.10.

Insiders Place Their Bets

In other news, SVP Jolanda Howe sold 750 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $32,115.00. Following the completion of the sale, the senior vice president now owns 2,926 shares in the company, valued at $125,291.32. The trade was a 20.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Peter Radovich sold 1,998 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total value of $85,554.36. Following the sale, the chief operating officer now owns 27,015 shares of the company’s stock, valued at approximately $1,156,782.30. This represents a 6.89 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 40,915 shares of company stock worth $1,897,920. 22.87% of the stock is owned by corporate insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.